PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32911375-4	2020	Ibrutinib significantly decreased pathologically high circulating B cells, regulatory T cells, effector/memory CD4+ and CD8+ T cells (including exhausted and chronically activated T cells), natural killer (NK) T cells, and myeloid-derived suppressor cells; preserved naive T cells and NK cells; and increased circulating classical monocytes.	ibrutinib	0-9	CD4 molecule	Homo sapiens	111-114	
30149317-8	2018	The long-term administration of ibrutinib was associated with the increased numbers of CD4+ bearing HLA-DR (P = 0.006) and elevation of HLA-DR expression on all monocyte subsets (P <= 0.004).	ibrutinib	32-41	CD4 molecule	Homo sapiens	87-90	
30938714-8	2019	Ex vivo expansion of T-cells and proportions of CD4+/CD8+ CAR T-cells with CD62L+CD127+ immunophenotype were significantly greater in patients on ibrutinib at leukapheresis.	ibrutinib	146-155	CD4 molecule	Homo sapiens	48-51	
35179349-8	2022	The boosted antitumor immunity was achieved mainly by the inhibition of Bruton"s tyrosine kinase activation mediated by ibrutinib, which reduced the proportion of TIBs, enhanced infiltration of CD8+ and CD4+ T cells, increased the secretion of immunogenic cytokines including IL-2 and IFN-gamma, and inhibited the proliferation of regulatory T cells and secretion of immunosuppressive cytokines including IL-10, IL-4, and TGF-beta.	ibrutinib	120-129	CD4 molecule	Homo sapiens	203-206	
29285806-1	2018	OBJECTIVE: Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK) in B lymphocytes as well as other kinases including interleukin-2-inducible T-cell kinase (ITK) in CD4+ Th2 regulatory T cells.	ibrutinib	11-20	CD4 molecule	Homo sapiens	181-184